KCM
PACB icon

Kennedy Capital Management’s Pacific Biosciences PACB Stock Holding History

Kennedy Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,131
Closed -$64.2K – 738
2024
Q1 		$64.2K Buy
+17,131
New +$100K ﹤0.01% 720
2023
Q3 		– Sell
-27,012
Closed -$359K – 701
2023
Q2 		$359K Buy
+27,012
New +$328K 0.01% 625
2023
Q1 		– Sell
-241,727
Closed -$1.98M – 640
2022
Q4 		$1.98M Sell
241,727
-107,200
-31% -$924K 0.06% 415
2022
Q3 		$2.03M Buy
+348,927
New +$2M 0.06% 414
2022
Q1 		– Sell
-220,106
Closed -$4.5M – 626
2021
Q4 		$4.5M Buy
220,106
+134,269
+156% +$3.24M 0.09% 369
2021
Q3 		$2.19M Buy
+85,837
New +$2.54M 0.05% 467
2017
Q3 		– Sell
-1,240,391
Closed -$4.42M – 754
2017
Q2 		$4.42M Buy
1,240,391
+426,269
+52% +$1.72M 0.08% 440
2017
Q1 		$4.21M Buy
814,122
+961
+0.1% +$4.7K 0.07% 462
2016
Q4 		$3.09M Buy
813,161
+685,080
+535% +$4.98M 0.05% 525
2016
Q3 		$1.15M Buy
+128,081
New +$1.07M 0.02% 644

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's PACB Position: Q2 2024 in Review

Kennedy Capital Management sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 17,131 shares — an estimated $64.2K sold.

Kennedy Capital Management first reported a position in PACB in Q3 2016 and held it in 10 quarters. The position peaked at $4.5M in Q4 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Kennedy Capital Management reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 17,131 Pacific Biosciences shares in Q2 2024, an estimated $64.2K.
  • Kennedy Capital Management first reported a position in Pacific Biosciences in Q3 2016 and held it in 10 quarters.
  • Kennedy Capital Management's Pacific Biosciences position peaked at $4.5M in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Kennedy Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.